Veracyte, Inc. (NASDAQ:VCYT) is among the 12 Best Genomics Stocks to Invest In.
The Fly reported on December 2, 2025, that Morgan Stanley began covering Veracyte, Inc. (NASDAQ:VCYT) with an Underweight rating and a price target of $48, up from $40. According to the firm, the Life Science Tools and Diagnostics end markets are showing rising bright spots, and various catalysts will be present across its coverage by 2026. Nonetheless, multiples are now at fair levels due to an industry valuation surge in the second part of the year. As a result, Morgan Stanley started the group with an In-Line industry perspective and designated Danaher as its Top Pick.
Veracyte, Inc. (NASDAQ:VCYT) also boosted guidance for the entire year 2025. The total sales forecast went from $496 million to $504 million to $506 million to $510 million. Meanwhile, testing revenue projections increased from $477 million to $483 million to $484 million to $487 million. The guidance for adjusted EBITDA margin has been elevated from 23.5% to over 25%. Testing sales growth was previously predicted to be between 14% and 15%, but it is now anticipated to be 16%. The company anticipates that without certain extra expenditures, the adjusted EBITDA margin will be roughly 25% in the fourth quarter and in subsequent years.
Veracyte, Inc. (NASDAQ:VCYT) is a company that does genomic diagnostics.
While we acknowledge the potential of VCYT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.
Disclosure. None
